Jupiter Life Line Hospitals Limited

JLHLHospital
1351.20+0.00 (+0.00%)
As on 30 Jan 2026, 01:39 pmMarket Closed

Fundamental Score

...

Jupiter Life Line Hospitals Limited Share Price Live NSE/BSE

No data
High
0.00
Low
0.00
Volume
0
Change
+0.00%

Profitability Metrics

Poor

Return on Equity

14.95%
Good

Return on Capital Employed

17.95%
Excellent

Operating Profit Margin (5Y)

21.60%
Poor

Dividend Yield

0.07%

Valuation Metrics

Average

Price to Earnings

48.76x

Market Capitalization

9.68K (Cr)

Industry P/E

52.84x

Growth Metrics

Poor

YoY Quarterly Profit Growth

11.04%
Good

YoY Quarterly Sales Growth

17.48%
Excellent

Sales Growth (5Y)

22.20%
Excellent

EPS Growth (5Y)

36.51%
Excellent

Profit Growth (5Y)

43.62%

Financial Health

Excellent

Debt to Equity

0.28x
Excellent

Interest Coverage

11.82x
Poor

Free Cash Flow (5Y)

-69.50 (Cr)

Ownership Structure

Average

Promoter Holding

40.91%
Average

FII Holding

9.06%
Good

DII Holding

16.97%
Excellent

Pledged Percentage

0.00%
Market-cap Classification
Mid-cap
Balance of growth potential and stability.
40.91%
Promoter Holding
9.68K (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of JLHL across key market metrics for learning purposes.

Positive Indicators

10 factors identified

Excellent ROCE Performance (17.95%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.

Strong Operating Margins (21.60%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.

Strong Revenue Growth (17.48%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.

Consistent Growth Track Record (22.20% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.

Excellent EPS Growth (36.51% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.

Strong Profit Growth Track Record (43.62% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.

Conservative Debt Levels (D/E: 0.28)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.

Strong Interest Coverage (11.82x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.

Strong Institutional Confidence (FII+DII: 26.03%)

Observation: Significant professional investor participation indicates quality recognition.

Analysis: High institutional holding often signals thorough due diligence and quality business fundamentals.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral, reducing forced-selling risk.

Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.

Risk Factors

3 factors identified

Premium Valuation Risk (P/E: 48.76x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.

Negative Free Cash Flow (₹-69.50 Cr over 5Y)

Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.

Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.

High P/E Ratio

Observation: Stock may be overvalued relative to earnings.

Analysis: P/E above 30 requires strong growth execution to justify current valuations.

Financial Statements

Comprehensive financial data for Jupiter Life Line Hospitals Limited

About JLHL

Business Overview

Jupiter Life Line Hospitals Limited, a multi-specialty hospital, provides health care services under the Jupiter brand in India. The company offers treatments in the areas of bariatric surgery, breast care center, cardiac surgery, cardiology, chest medicine, dental care, dermatology, endocrinology and diabetes, ENT, gastroenterology, general surgery and minimal access surgery, hematology and BMT, HPB and surgical gastroenterology, infectious diseases, internal medicine, interventional radiology, mental health, nephrology, neurology, neurosurgery, nutrition and dietetics, Obs and gynecology, oncology, ophthalmology, organ transplant, orthopedics, pediatrics, pain clinic, plastic and cosmetic surgery, rehabilitation, rheumatology, robotic knee replacement, robotic surgery, TAVI/TAVR, and urology. It also operates hotel under the Fortune Park Lake City Hotel name in Thane. The company was incorporated in 2002 and is based in Mumbai, India.

Company Details

Symbol:JLHL
Industry:Hospital
Sector:Hospital

Key Leadership

Dr. Ajay Pratap Thakker
Chairman & MD
Dr. Ankit Ajay Thakker
Joint MD, CEO & Executive Director
Mr. Harshad Purani
CFO and President of Administration & Head of Corporate Social Responsibility

Corporate Events

Recent
Ex-Dividend Date
2025-07-04

JLHL Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)14.95%
Return on Capital Employed17.95%
Operating Profit Margin (5Y)21.60%
Debt to Equity Ratio0.28
Interest Coverage Ratio11.82

Growth & Valuation

Sales Growth (5Y)22.20%
Profit Growth (5Y)43.62%
EPS Growth (5Y)36.51%
YoY Quarterly Profit Growth11.04%
YoY Quarterly Sales Growth17.48%

Frequently Asked Questions

What is the current price of Jupiter Life Line Hospitals Limited (JLHL)?

As of 30 Jan 2026, 01:39 pm IST, Jupiter Life Line Hospitals Limited (JLHL) is currently trading at ₹1351.20. The stock has a market capitalization of ₹9.68K (Cr).

Is JLHL share price Overvalued or Undervalued?

JLHL is currently trading at a P/E ratio of 48.76x, compared to the industry average of 52.84x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.

What factors affect the Jupiter Life Line Hospitals Limited share price?

Key factors influencing JLHL's price include its quarterly earnings growth (Sales Growth: 17.48%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is Jupiter Life Line Hospitals Limited a good stock for long-term investment?

Jupiter Life Line Hospitals Limited shows a 5-year Profit Growth of 43.62% and an ROE of 14.95%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.28 before investing.

How does Jupiter Life Line Hospitals Limited compare with its industry peers?

Jupiter Life Line Hospitals Limited competes with major peers in the Hospital. Investors should compare JLHL's P/E of 48.76x and ROE of 14.95% against the industry averages to determine its competitive standing.

What is the P/E ratio of JLHL and what does it mean?

JLHL has a P/E ratio of 48.76x compared to the industry average of 52.84x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹49 for every ₹1 of annual earnings.

How is JLHL performing according to Bull Run's analysis?

JLHL has a Bull Run fundamental score of 62.9/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.

What sector and industry does JLHL belong to?

JLHL operates in the Hospital industry. This classification helps understand the competitive landscape and sector-specific trends affecting Jupiter Life Line Hospitals Limited.

What is Return on Equity (ROE) and why is it important for JLHL?

JLHL has an ROE of 14.95%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Jupiter Life Line Hospitals Limited generates profits from shareholders' equity.

How is JLHL's debt-to-equity ratio and what does it indicate?

JLHL has a debt-to-equity ratio of 0.28, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.

What is JLHL's dividend yield and is it a good dividend stock?

JLHL offers a dividend yield of 0.07%, which means you receive ₹0.07 annual dividend for every ₹100 invested.

How has JLHL grown over the past 5 years?

JLHL has achieved 5-year growth rates of: Sales Growth 22.20%, Profit Growth 43.62%, and EPS Growth 36.51%.

What is the promoter holding in JLHL and why does it matter?

Promoters hold 40.91% of JLHL shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.

What is JLHL's market capitalization category?

JLHL has a market capitalization of ₹9678 crores, placing it in the Mid-cap category.

How volatile is JLHL stock?

JLHL has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is the 52-week high and low for JLHL?

JLHL has a 52-week high of ₹N/A and low of ₹N/A.

What is JLHL's operating profit margin trend?

JLHL has a 5-year average Operating Profit Margin (OPM) of 21.60%, indicating the company's operational efficiency.

How is JLHL's quarterly performance?

Recent quarterly performance shows YoY Sales Growth of 17.48% and YoY Profit Growth of 11.04%.

What is the institutional holding pattern in JLHL?

JLHL has FII holding of 9.06% and DII holding of 16.97%. Significant institutional holding often suggests professional confidence in the stock.